Pfizer (PFE) Lowers FY Revenue Range to $67B-$70B from $67B-$71B
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Pfizer Reports Second-Quarter 2023 Results
August 1, 2023 6:45 AM EDTSecond-Quarter 2023 Revenues of $12.7 Billion Expected Decline in Paxlovid and Comirnaty(1) Revenues Drove 53% Operational Decrease in Second-Quarter 2023 Revenues Second-Quarter 2023 Revenues from Comirnaty(1) and Paxlovid of $1.6 Billion Excluding Contributions from Comirnaty(1) and Paxlovid, Revenues Grew 5% Operationally Second-Quarter 2023 Reported Diluted EPS(2) of $0.41, a Year-Over-Year Decline of 77%, and Adjusted Diluted EPS(3) of $0.67, a Year-Over-Year Decline of 67% Narrows 2023 Revenue Guidance(4) Range to $67 to $70 Billion and Adjusts 2023 Non-COVID Operational Revenue Growth Expectation to 6% to 8% Maintains All Other Components of Full-Year 2023 Financial Guidance(4), Including Guidance for Adjusted Diluted... More
